Century Therapeutics, Inc. (IPSC)
NASDAQ: IPSC · Real-Time Price · USD
2.385
+0.080 (3.47%)
At close: May 28, 2026, 4:00 PM EDT
2.400
+0.015 (0.63%)
After-hours: May 28, 2026, 4:31 PM EDT
Century Therapeutics Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, Century Therapeutics stock has a consensus rating of "Buy" and an average price target of $3.67. The average 1-year stock price forecast is 53.88% higher than the current stock price, while the lowest is $2.00 (-16.14%) and the highest is $5.00 (+109.64%).
Price Target: $3.67 (+53.88%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Century Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 1 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 5 | 3 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho Securities | Mizuho Securities | Buy Initiates $8 | Buy | Initiates | $8 | +235.43% | May 27, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $5 | Buy | Reiterates | $5 | +109.64% | May 26, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $4 | Buy | Reiterates | $4 | +67.71% | May 14, 2026 |
| TD Cowen | TD Cowen | Buy Maintains n/a | Buy | Maintains | n/a | n/a | May 13, 2026 |
| Clear Street | Clear Street | Buy Maintains $6.6 | Buy | Maintains | $6.6 | +176.73% | Mar 12, 2026 |
Financial Forecast
Revenue This Year
n/a
from 109.16M
Revenue Next Year
n/a
EPS This Year
-0.64
from -0.11
EPS Next Year
-0.57
from -0.64
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.41 | -0.35 | |||
| Avg | -0.64 | -0.57 | |||
| Low | -0.98 | -0.87 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.